Spread the love

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Luteolin, a flavone with an antioxidant and anti-inflammatory activity, inhibits osteoporosis and bone metastasis via up regulation of its target gene.  This study may suggest that Luteolin, by up regulating its target gene, it may suppress the expression of Tgif2. Together, this study suggests that pharmacological formulations encompassing ” Luteolin or its analogues” can be used to inhibit osteoporosis and bone metastasis. 

Idea Proposed/Formulated by: Dr L Boominathan PhD

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Courtesy: When you cite drop us a line at info@genomediscovery.org

CitationBoominathan, Molecular and Therapeutic insights into Osteoclastogenesis and its associated disorders: Luteolin, a flavone with an antioxidant and anti-inflammatory activity, inhibits osteoporosis and bone metastasis via up regulation of its target gene, 26/July/2014, 5.00 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

*Research cooperation


Spread the love